Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:KURANASDAQ:URGNNASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.59+1.0%$1.85$0.91▼$6.05$216.39M2.152.60 million shs1.91 million shsKURAKura Oncology$5.91+1.7%$6.12$5.41▼$23.48$511.63M0.41.25 million shs781,540 shsURGNUrogen Pharma$13.49+4.1%$9.67$3.42▼$18.15$622.02M1.021.08 million shs737,414 shsZYBTZhengye Biotechnology$6.05+2.2%$8.41$3.50▼$14.30$285.38MN/A330,365 shs124,393 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine0.00%+13.38%+35.34%+158.50%-43.68%KURAKura Oncology0.00%+4.23%-12.18%+2.60%-70.46%URGNUrogen Pharma0.00%0.00%+83.04%+35.44%-15.05%ZYBTZhengye Biotechnology0.00%-8.47%+2.37%+57.14%+604,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.191 of 5 stars3.23.00.04.31.92.50.6KURAKura Oncology4.5667 of 5 stars4.43.00.04.71.90.80.6URGNUrogen Pharma4.4769 of 5 stars4.52.00.04.51.92.50.0ZYBTZhengye BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.31Hold$4.7081.82% UpsideKURAKura Oncology 2.86Moderate Buy$24.50314.55% UpsideURGNUrogen Pharma 3.00Buy$32.86143.57% UpsideZYBTZhengye Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EDIT, KURA, ZYBT, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/16/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.006/13/2025URGNUrogen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$16.006/13/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Buy$31.006/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/13/2025URGNUrogen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.006/13/2025URGNUrogen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $30.006/12/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.006/3/2025URGNUrogen PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$36.00 ➝ $10.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M6.70N/AN/A$1.63 per share1.59KURAKura Oncology$53.88M9.50N/AN/A$5.32 per share1.11URGNUrogen Pharma$90.40M6.88N/AN/A($0.21) per share-64.24ZYBTZhengye Biotechnology$25.53M11.18N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)KURAKura Oncology-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)ZYBTZhengye BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ALatest EDIT, KURA, ZYBT, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/12/2025Q1 2025URGNUrogen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.083.08KURAKura Oncology0.028.078.07URGNUrogen PharmaN/A5.655.47ZYBTZhengye BiotechnologyN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%KURAKura OncologyN/AURGNUrogen Pharma91.29%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%KURAKura Oncology6.40%URGNUrogen Pharma5.10%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23083.71 million82.12 millionOptionableKURAKura Oncology13086.57 million81.03 millionOptionableURGNUrogen Pharma20046.11 million43.76 millionOptionableZYBTZhengye Biotechnology27847.17 millionN/AN/AEDIT, KURA, ZYBT, and URGN HeadlinesRecent News About These CompaniesZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comZhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) Lock-Up Period Will End on July 7thJune 30, 2025 | marketbeat.comZYBT - Zhengye Biotechnology Holding Ltd Chart - MorningstarJune 27, 2025 | morningstar.comMZhengye Biotechnology Holding LtdJune 21, 2025 | morningstar.comMZhengye Biotechnology (NASDAQ:ZYBT) Trading Down 6% - Time to Sell?June 7, 2025 | marketbeat.comZYBT Zhengye Biotechnology Holding LimitedMay 30, 2025 | seekingalpha.comZhengye Biotechnology faces NASDAQ compliance issueMay 24, 2025 | investing.comZhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing RequirementsMay 23, 2025 | quiverquant.comQZhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-FMay 23, 2025 | globenewswire.comShould We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?April 7, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd.April 3, 2025 | wsj.comZhengye Biotechnology Holding Limited (ZYBT)March 27, 2025 | finance.yahoo.comZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment OptionJanuary 14, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Closing of Initial Public OfferingJanuary 8, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Pricing of Initial Public OfferingJanuary 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeCapitalize on Volatility: 3 Finance Stocks Thriving in 2025By Chris Markoch | July 2, 2025View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025EDIT, KURA, ZYBT, and URGN Company DescriptionsEditas Medicine NASDAQ:EDIT$2.58 +0.03 (+0.98%) Closing price 07/3/2025 03:48 PM EasternExtended Trading$2.55 -0.04 (-1.35%) As of 05:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Kura Oncology NASDAQ:KURA$5.91 +0.10 (+1.72%) Closing price 07/3/2025 03:35 PM EasternExtended Trading$5.83 -0.08 (-1.37%) As of 06:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Urogen Pharma NASDAQ:URGN$13.49 +0.53 (+4.09%) Closing price 07/3/2025 03:11 PM EasternExtended Trading$13.18 -0.31 (-2.33%) As of 06:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Zhengye Biotechnology NASDAQ:ZYBT$6.05 +0.13 (+2.20%) As of 07/3/2025 01:00 PM EasternZhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
